A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma.

Trial Profile

A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2013

At a glance

  • Drugs Vorinostat (Primary) ; Bevacizumab; Irinotecan
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 May 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
    • 11 Dec 2012 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top